On 27 February 2024, the AI-POD consortium and External Advisory Board convened at the Austria Centre Vienna for their annual consortium meeting, which was held as a hybrid session. The focal point of discussion focused on progress in AI-based risk prediction for obesity-related heart disease.
High-ranking members of the External Advisory Board, including Bjoern Menze, Rozemarijn Vliegenthart, Matthias Blüher, and Angeliki Kerasidou, took part in the event. They were joined by representatives from our project partners: Universitätsklinikum Bonn, The European Institute for Biomedical Imaging Research, the Medical University of Vienna, Collective Minds Radiology, the University Hospital in Pilsen, the Charles University, Universitätsmedizin Mannheim, KU Leuven, Medicalvalues GmbH, Brightfish, Universitätsspital Zürich, and the Imperial College London.
Discussions during the AI-POD Consortium and External Advisory Board meeting focused on the critical steps required to successfully conduct the prospective clinical study planned as part of the project. Key stakeholders deliberated meticulously on various aspects ranging from ethics applications to technical installations. Of utmost importance was the start of patient enrolment by the end of April, for which careful planning is underway. On the agenda were discussions on ethics applications and study protocols, patient engagement strategies, technical preparations, content creation, translation, dissemination activities, project management and reporting. Each aspect was scrutinized to ensure smooth execution of the project aiming to advance obesity-related disease prediction for cardiovascular disease.
The collaborative spirit and careful planning demonstrated at the meeting underscored the collective commitment to working on the AI-POD project. The combined efforts of the stakeholders, coupled with a clear roadmap and action items, signal a promising path forward for the AI-POD consortium. As the project progresses, the shared commitment to tackling obesity-related heart disease remains in place, setting a solid foundation for future breakthroughs in medical science and patient care.
